↘️ Hims & Hers Health (HIMS): The telehealth provider's shares fell 11%. On Wednesday, the FDA said there were no longer shortages of Eli Lilly (LLY)'s hugely popular Zepbound and Mounjaro drugs. Hims & Hers had taken advantage of the short supply to sell compounded versions. Read More...
↘️ Hims & Hers Health (HIMS): The telehealth provider’s shares fell 11%. On Wednesday, the FDA said there were no longer shortages of Eli Lilly (LLY)’s hugely popular Zepbound and Mounjaro drugs. Hims & Hers had taken advantage of the short supply to sell compounded versions.
Add Comment